In other words, the investigation of KRAS mutation in lung cancer, prognosis evaluation for patients with BRAF or RAS mutations, and elucidation of EGFR’s role in NSCLC and lung adenocarcinoma represent pivotal research directions within this field that have made significant advancements. Here, EGFR is linked to non-small cell lung carcinoma.